Commodity Channel Index
Previous Close | 5.65 |
Open | 5.71 |
Bid | 6.09 x 3000 |
Ask | 6.36 x 1200 |
Day's Range | 5.70 - 6.48 |
52 Week Range | 2.00 - 10.30 |
Volume | |
Avg. Volume | 180,301 |
Market Cap | 113.296M |
Beta (5Y Monthly) | 1.53 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.48 |
Earnings Date | Aug 09, 2023 - Aug 14, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 29.00 |
SEATTLE and VANCOUVER, British Columbia, May 25, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 3,000,000 shares of common stock at a price of $5.50 per share in a registe
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT ORCA-3 Topline Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported topline results from the second Phase III pivotal trial of cytisinicline on May 23, 2023. Results were discussed with analysts and investors in a conference call held that morning. On average, odds ratios were lower than that achieved in ORCA-2, but
With the business potentially at an important milestone, we thought we'd take a closer look at Achieve Life Sciences...
Achieve Life Sciences Inc (NASDAQ: ACHV) announced topline results from the second Phase 3 ORCA-3 trial of cytisinicline. Consistent with the previously reported Phase 3 ORCA-2 study, ORCA-3 showed a statistically significant benefit in helping people to quit smoking compared to placebo, with low rates of adverse events. The 6- and 12-week cytisinicline treatment durations demonstrated statistically significant smoking cessation on the primary and secondary efficacy analyses compared to placebo.
ORCA-3 demonstrated statistically significant topline results in primary and secondary smoking cessation endpoints for both 6- and 12-week cytisinicline treatment durations compared to placebo Cytisinicline demonstrated 6x increase in odds of continuous smoking abstinence at 6 months Cytisinicline treatment well tolerated with low rates of adverse events reported Management to host conference call today, May 23 at 8:30AM EDT SEATTLE and VANCOUVER, British Columbia, May 23, 2023 (GLOBE NEWSWIRE)
Refinanced Loan Extends Maturity to December 2024SEATTLE and VANCOUVER, British Columbia, May 17, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced the Company has refinanced its previous debt agreement with Silicon Valley Bank (SVB), a division of First-Citizens Bank. The Company and SVB have entered into
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT First Quarter 2023 Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported first quarter 2023 results in a press release and held a conference call after market close on May 9, 2022. The company concurrently filed its Form 10-Q with the SEC. 2023 highlights to date include impressive topline results from the ORCA-V1
Q1 2023 Achieve Life Sciences Inc Earnings Call
Company to host conference call at 4:30 PM EDT today, May 9, 2023SEATTLE and VANCOUVER, British Columbia, May 09, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced first quarter 2023 financial results and provided an update on the cytisinicline development program. Recent Business Highlights Released posit
SEATTLE and VANCOUVER, British Columbia, April 26, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its first quarter 2023 financial results and provide an update on the cytisinicline development program on Tuesday, May 9, 2023 at 4:30 PM EDT. To access the webcast, please use the
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Phase II Vaping Trial (ORCA-V1) Trial Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted results from its Ongoing Research of Cytisinicline for Addiction, Vaping (ORCA-V1) trial and hosted a conference call for investors on April 20, 2023. The Phase II ORCA-V1 trial was conducted to measure the safety and effectiveness
Achieve Life Sciences Inc (NASDAQ: ACHV) reported topline results from its Phase 2 ORCA-V1 trial evaluating 3mg cytisinicline dosed three times daily for 12 weeks compared to placebo in 160 adults who use e-cigarettes or nicotine vapes and who do not currently smoke cigarettes. Subjects who received 12 weeks of cytisinicline treatment had 2.6 times higher odds, or likelihood, to have quit vaping during the last four weeks of treatment compared to subjects who received a placebo (p=0.035). The va
First Randomized, Placebo-Controlled Clinical Study to Report Successful E-Cigarette Cessation Benefit with Pharmacological Treatment Study Supports Potential Broad Utilization of Cytisinicline for Treatment of Nicotine Dependence Management to Host Conference Call Today, April 20, 2023, at 8:30 AM EDT SEATTLE and VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and
SEATTLE and VANCOUVER, British Columbia, April 14, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of Achieve, will present at the Life Science Innovation Northwest (LSINW) 2023 Conference being held at the Seattle Convention Center April 25-26, 2023. The Achieve corporate presenta
SEATTLE, Wash. and VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced changes to the Company’s Board of Directors to continue to support the future direction of the Company.As provided in the previously reported Cooperation Agreement, as amended, between the Company an
Topline Data Expected in 2Q 2023SEATTLE, Wash. and VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the last study follow-up visit for the last subject enrolled in the Phase 3 ORCA-3 trial has occurred.“We are pleased to have reached this final milestone in the
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q4 2022 Earnings Call Transcript March 16, 2023 Operator: Hello and welcome to the Achieve Life Sciences Fourth Quarter 2022 Earnings Conference Call and Webcast. As a reminder, this conference is being recorded. It’s now my pleasure to turn the call over to Nicole Jones with CG Capital. Please go […]
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported 2022 results in a press release and held a conference call after market close on March 16, 2023. The company concurrently filed its Form 10-K with the SEC. Since our previous update , Achieve has announced that the last subjects in both its ORCA-V1 and ORCA-3 have been
SEATTLE, Wash. and VANCOUVER, British Columbia, March 17, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the Company has issued an inducement grant of stock options to a new employee. Achieve’s Board of Directors approved the new employment inducement grant to purchase 25,000 shares of Achieve’s co
Q4 2022 Achieve Life Sciences Inc Earnings Call
Company to host conference call March 16, 2023, at 4:30 PM EDTSEATTLE, Wash. and VANCOUVER, British Columbia, March 16, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced fourth quarter and year-end 2022 financial results and provided an update on the cytisinicline development program. Recent Highl
Topline Data Expected in 2Q 2023SEATTLE, Wash. and VANCOUVER, British Columbia, March 08, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the last study follow-up visit for the last subject enrolled in the Phase 2 ORCA-V1 trial has occurred.ORCA-V1 is evaluating the efficacy and safety of c
SEATTLE, Wash. and VANCOUVER, British Columbia, March 03, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, announced data from the Phase 3 ORCA-2 trial will be presented at the Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting, being held in San Antonio, TX, March 1-4, 2023.Additional findings f
SEATTLE, Wash and VANCOUVER, British Columbia, March 02, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its fourth quarter and year-end 2022 financial results and provide an update on the cytisinicline development program on Thursday, March 16, 2023 at 4:30 PM EDT.To access the w
If you want to know who really controls Achieve Life Sciences, Inc. ( NASDAQ:ACHV ), then you'll have to look at the...